Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN) Dec 22, 2022
Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022 Nov 7, 2022
Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia Sep 13, 2022
Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference Sep 12, 2022
